GlassScriptPhysician profile
Rajesh Sharma
NPI 1891004388
$88,577.94
in general payments reported to CMS, 2019-2025
28 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,767 · 2020: $2,019 · 2021: $27K · 2022: $17K · 2023: $24K · 2024: $14K · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,834 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000 · Travel and Lodging: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,695.00 |
| Food and Beverage | $5,833.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
| Travel and Lodging | $2,360.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $43,614.24 | 2019-2024 | Senza, Omnia |
| Vertos Medical, INC. | $25,576.18 | 2019-2024 | Mild Device Kit |
| Spinal Simplicity, LLC | $9,024.45 | 2020-2025 | Ha Minuteman G3-R |
| Abbott Laboratories | $6,552.39 | 2019-2025 | Proclaim, Eterna, Octrode |
| Stryker Corporation | $1,003.58 | 2023 | Spinejack |
| Boston Scientific Corporation | $369.04 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Foundation Fusion Solutions, LLC | $360.78 | 2020 | |
| Globus Medical, INC. | $346.79 | 2025 | Senza, Vyrsa V1 |
| Si-Bone, INC. | $267.17 | 2019 | |
| Abbvie INC. | $234.19 | 2021-2024 | Botox, Qulipta |
| Pfizer INC. | $209.48 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $167.10 | 2022 | |
| Biotronik Nro, INC. | $110.60 | 2024 | Prospera |
| Biotronik INC. | $107.76 | 2025 | Acticor 7 Vr-T Dx |
| Medtronic, INC. | $105.90 | 2021-2025 | Intellis Adaptivestim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Canon Medical Systems USA, INC. | $103.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $99.26 | 2019 | |
| Saluda Medical Americas, INC. | $85.26 | 2025 | Evoke |
| Biohaven Pharmaceuticals, INC. | $44.38 | 2021 | |
| Scilex Pharmaceuticals INC. | $35.14 | 2023 | Ztlido |
| Spr Therapeutics, INC | $34.36 | 2019 | |
| Allergan, INC. | $29.92 | 2020-2022 | |
| Averitas Pharma INC. | $20.95 | 2023 | Qutenza |
| Medtronic USA, INC. | $16.56 | 2020 | |
| Fidia Pharma USA INC. | $16.47 | 2023 | Hymovis, Triluron |
| Collegium Pharmaceutical, INC. | $15.57 | 2023 | Xtampza |
| Curonix LLC | $15.39 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Lilly USA, LLC | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$432,786.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.